E-test susceptibility results of Brucella strains for streptomycin, rifampicin, ciprofloxacin and tetracycline;Brucella suşlarιnιn streptomisin, rifampisin, siprofloksasin ve tetrasiklin için E-test duyarlιlιk sonuçlarι

Mikrobiyoloji Bulteni

Volumn 40, Issue 3, 2006, Pages 265-268

  Sengoz G ^a   Kart Yasar K ^a   Bati Kutlu, S ^a   Bilgin Durdu, Y ^a   Ozdemir R ^a   Nazlican, O ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Antimicrobial susceptibility; Brucella; E test

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ARTICLE; BRUCELLA; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; BRUCELLA; CIPROFLOXACIN; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; STREPTOMYCIN; TETRACYCLINE;

EID: 39049176430     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Young EJ. Brucella species, p: 2389. In: Mandell GL, Bennett JE, Dolin R (eds), Principles and Practice of Infectious Diseases. 2000, 5th ed. Churchill Livingstone, Philadelphia.
2. Gobernado M, Canton E, Santos M. In vitro activity of ciprofloxacin against Brucella melitensis (Letter). Eur J Clin Microbiol 1984; 3: 371.
3. Bilgehan H. Aerop Gram olumsuz küçük basiller, s: 199- 228. Klinik Mikrobryoloji; Özel Bakteriyoloji ve Bakteri Enfeksiyonlari. 2000, 10.baski. Bariş Yayinlari Fakülteler Kitabevi, Izmir.
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 12th Informational Supplement. NCCLS Document M100-S12, Vol: 22, 2002. CLSI, Wayne, Pa.
5. Wiedemann B, Grimm H. Susceptibility to antibiotics: species incidence and trends, p: 900. In: Lorian V (ed), Antibiotics in Laboratory Medicine. 1996, 4th, ed. Williams and Wilkins, Baltimore, USA.
6. Bocsh J, Linares J, Lopez de Goicoechea MJ, Ariza J, Cisnal MC, Martin R. In vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother 1986; 17: 459-61.
7. Wendel HW. Modern chemotherapy for bruceilosis in humans. Rev Infect Dis 1990; 12: 1060-99.
8. Ariza J, Bosch J, Gudiol F, Linares J, Vildarich PF, Martin R. Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother 1986; 30: 958-60.
9. Gür D, Kocagöz S, Akova M, Ünal S. Comparison of E-test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 2337-9.
10. Bodur H, Balaban N, Aksaray S, et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Inf Dis 2003; 35: 337-8.
11. Baykam N, Esener H, Ergönül Ö, Eren Ş, Çelikbaş AK, Dokuzoǧuz B. Invitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23: 405-7.
12. Quadri SMH, Ueno Y. Antibacterial activity of the new fluoroquinolone CI-960 against clinical isolates of Brucella melitensis and its comparison with ciprofloxacin, lomefloxacin, fleroxacin, pefloxacin and norfloxacin (Abstract), p: 185. In: Tümbay E, Hilmi S, Anǧ Ö (eds), Brucella and Brucellosis in Man and Animals. 1991, Turkish Microbiology Society Publication, Vol: 16. Istanbul.
13. Akova M, Uzun Ö, Akalin HE, Hayran M, Ünal S, Gür D. Quinolones in the treatment of human brucellosis. Comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831-4.
14. Al Sibia MB, Halim MA, El-Shaker MM, Khan BA, Quadri SMH. Efficacy of ciprofloxacin for the treatment of Brucella melitensis infections. Antimicrob Agents Chemother 1992; 36: 150-2.
15. Lang R, Banai M, Lishner M, Rubinstein E. Brucellosis. Int J Antimicrob Agents 1995; 5: 2003-8.